Pharvaris (PHVS) Cash from Operations (2020 - 2026)
Pharvaris (PHVS) reported Cash from Operations of 57092530.86 for Q1 2026, down 41.08% on a YoY basis from 96901332.11 in Q1 2025, and down 29.23% quarter-over-quarter from 44178661.81 in Q4 2025.
Pharvaris (PHVS) Cash from Operations (2020 - 2026) Analysis & Trends
Pharvaris has reported Cash from Operations for 7 years, with the latest figure at 57092530.86 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 41.08% year-over-year to 57092530.86; the trailing twelve-month figure through Mar 2026 stood at 2539079577625.18 (up 129.3% YoY), and the FY2025 full-year result was 154867325.53, down 19.11% from the prior year.
- Cash from Operations for Q1 2026 stood at 57092530.86, down from 44178661.81 in the prior quarter.
- The five-year high for Cash from Operations was 80023999980396.0 in Q3 2025, with the low at 77484819131578.14 in Q2 2025.
- Historically, Cash from Operations has averaged 213583959260.49 across 5 years, with a median of 26324513.02 in 2024.
- The largest YoY upside for Cash from Operations was 324922255.76% in 2023 against a maximum downside of 340632884.32% in 2023.
- Pharvaris' Cash from Operations stood at 20826281.92 in 2022, then fell by 23.0% to 25616942.47 in 2023, then slumped by 45.81% to 37351343.8 in 2024, then fell by 18.28% to 44178661.81 in 2025, then fell by 29.23% to 57092530.86 in 2026.
- The last three Cash from Operations figures came in at 57092530.86 (Q1 2026), 44178661.81 (Q4 2025), and 80023999980396.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -57.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.09 Mn |
| Mar 31, 2026 | -57.09 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Sep 30, 2025 | 80,024.00 Bn |
| Sep 30, 2025 | 80,024.00 Bn |
| Jun 30, 2025 | -77,484.82 Bn |
| Jun 30, 2025 | -77,484.82 Bn |
| Mar 31, 2025 | -40.47 Mn |
| Mar 31, 2025 | -40.47 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Dec 31, 2024 | -37.35 Mn |
| Sep 30, 2024 | 57,013.95 Bn |
| Sep 30, 2024 | 57,013.95 Bn |
| Jun 30, 2024 | -55,906.57 Bn |
| Jun 30, 2024 | -55,906.57 Bn |
| Mar 31, 2024 | -26.32 Mn |
| Mar 31, 2024 | -26.32 Mn |
| Dec 31, 2023 | -25.62 Mn |
| Dec 31, 2023 | -25.62 Mn |